Avastin and Tarceva combo does not meet primary endpoint in Phase III NSCLC « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Avastin and Tarceva combo does not meet primary endpoint in Phase III NSCLC

Posted on October 6, 2008 by crimsoncanary

Phase III trial results show treatment with Avastin/Tarceva in patients with advanced NSCLC did not meet its primary endpoint (overall survival compared to Tarceva). Secondary endpoints of progression-free survival (PFS) and response rate when Avastin was added to Tarceva were however met.

Filed under: Uncategorized | Tagged: Avastin, bevacizumab, ErbB-1, ErbB1, erlotinib, Genentech, kinase, OSI, phase iii, Roche, Tarceva, VEGF

« Scripps Inst publish series of Rho kinase II inhibitors Vertex publish series of Syk kinase inhibitors »